Copyright
©The Author(s) 2019.
World J Cardiol. Mar 26, 2019; 11(3): 103-119
Published online Mar 26, 2019. doi: 10.4330/wjc.v11.i3.103
Published online Mar 26, 2019. doi: 10.4330/wjc.v11.i3.103
Table 1 Primary prevention implantable cardioverter defibrillator studies
Study | Intervention/control group | Inclusion criteria | Risk reduction of SCD with ICD |
Multicenter Automatic Defibrillator Implantation Trial[12] | ICD vs antiarrhythmic drug | Previous MI; EF ≤ 35%; nsVT; positive findings on EPS | 54% (P = 0.001) |
Multicenter Unsustained Tachycardia Trial[13] | EP-guided therapy vs placebo | Coronary disease; EF ≤ 40%; Non-sustained VT; inducible VT at EPS | 51% (P = 0.001) |
Multicenter Automatic Defibrillator Implantation Trial 2[14] | ICD vs optimal pharmacological treatment | Prior MI EF ≤ 30% | 31% (P = 0.02) |
Sudden Cardiac Death in Heart Failure Trial[15] | ICD vs optimal pharmacological therapy vs optimal pharmacological therapy + amiodarone | Ischaemic and non-ischaemic cardiomyopathy; EF ≤ 35% | 23% (P = 0.007) |
Defibrillator implantation in patients with nonischemic systolic heart failure[16] | ICD vs optimal pharmacological therapy | Non-ischaemic cardiomyopathy; EF ≤ 35% | 50% (P = 0.005) |
- Citation: Khan HM, Leslie SJ. Risk factors for sudden cardiac death to determine high risk patients in specific patient populations that may benefit from a wearable defibrillator. World J Cardiol 2019; 11(3): 103-119
- URL: https://www.wjgnet.com/1949-8462/full/v11/i3/103.htm
- DOI: https://dx.doi.org/10.4330/wjc.v11.i3.103